Clinical trials: Overweight and Obesity
Satiety, Appetite
A Study of NatureU Burn on Satiety in Healthy Adults
This single-center, single-blind, non-randomized crossover exploratory study evaluated the short-term effects of NatureU Burn on postprandial satiety in healthy adults.
- Conditions
- Satiety, Appetite, Food Intake, Fat Disorder
- Trial name
- NUBURN (NCT07597382)
- Testing
- Glucose Reference Food, NatureU Burn Plus Glucose
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- OmniSolutions Laboratory Holdings Limited
Obesity
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight.
- Trial name
- NCT04775082
- Testing
- Liraglutide
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 78 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Evaluation of Obex® in Overweight and Obesity
Obesity is an important and growing worldwide Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer Diverse adverse events have been reported with the use of antiobesity…
- Trial name
- NCT03541005
- Testing
- Obex
- Where
- Cuba
- Volunteers
- 160 people
- Sponsor
- Catalysis SL
Obesity
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 1 (NCT07339423)
- Testing
- NNC0487-0111
- Where
- 72 sites in United States, Argentina and 7 more
- Volunteers
- 1,150 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2
The purpose of this study is to determine whether the LAP-BAND system is safe and effective in subjects with BMI ≥ 30 kg/m2 and < 40 kg/m2.
- Trial name
- NCT00570505
- Testing
- LAP-BAND System
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- Apollo Endosurgery, Inc.
Overweight, Obesity
Effects of Obex in Overweight and Obese Patients
Obesity is an important and growing public health worldwide Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer An extensive body of evidence from efficacy trials has…
- Trial name
- NCT02145442
- Testing
- Obex
- Where
- Cuba
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Obesity
Effects of Fiber on Satiety
The effects of a dietary fiber on hunger and food intake will be tested in men and women. Participants will receive fiber as part of a breakfast meal on two occasions.
- Trial name
- NCT01588600
- Testing
- Dietary Fiber
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ingredion Incorporated
Obesity, Overweight
A Study of GZR18 Injection in Chinese Obese/Overweight Patients
The study was a multicenter, randomized, double-blind, placebo-controlled phase Ib/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in Chinese adult obese/overweight…
- Trial name
- NCT06256536
- Testing
- GZR18
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes, Obesity
Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity
The purpose of the registry was to observe the safety and effectiveness outcomes for subjects treated with the EndoBarrier in the post market setting where the product had Conformité Européene (CE mark) regulatory approval and in…
- Trial name
- NCT03072901
- Testing
- EndoBarrier Gastrointestinal Liner
- Volunteers
- 244 people
- Sponsor
- Morphic Medical Inc.
Cardiovascular Risk Factors, Hyperlipidemia
European Study of Cardiovascular Risk
The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.
- Conditions
- Cardiovascular Risk Factors, Hyperlipidemia, Hypertension, Diabetes
- Trial name
- EURIKA (NCT00882336)
- Where
- 775 sites in Austria, Belgium and 10 more
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Obesity
A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity
The purposes of this study are to compare the effects of Topiramate and placebo on abdominal visceral fat accumulation at 6 months and to evaluate the safety of Topiramate for up to 12 months of continued treatment in male…
- Trial name
- NCT00231608
- Testing
- topiramate
- Volunteers
- 68 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
- Trial name
- NCT06019559
- Testing
- K-757 120 mg BID and K-833 100 mg BID
- Where
- 22 sites in United States
- Volunteers
- 155 people
- Sponsor
- TriGemX Bio, Inc.
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study…
- Trial name
- NCT00796367
- Testing
- VI-0521
- Volunteers
- 676 people
- Sponsor
- VIVUS LLC
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity or Overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith1 (NCT07351045)
- Testing
- Enicepatide
- Where
- 209 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Obesity, Type 2 Diabetes
Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")
The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions Magnet System, GJ Biofragmentable ("MagGJ System") for creation of a side-to-side anastomosis for gastro-ileal or…
- Trial name
- NCT06073457
- Testing
- MagGJ System
- Where
- 4 sites in Canada, Chile and 2 more
- Volunteers
- 35 people
- Sponsor
- GT Metabolic Solutions, Inc.
22q11 Deletion Syndrome, DiGeorge Syndrome
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and…
- Conditions
- 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18
- Trial name
- SMART (NCT02381457)
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 20,960 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Obesity
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide.
- Trial name
- NCT06131437
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 46 sites in United States
- Volunteers
- 809 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.